1-6 of 6
Xavier Poiré
Close
Sort by
Journal Articles

High-Dose Therapy and Autologous Stem Cell Transplantation for Extra-Nodal NK/T Lymphoma in Western Patients; A Study From the European Group for Blood and Marrow Transplantation (EBMT).

Christopher P Fox, MD, PhD, Ariane Boumendil, Herve Finel, Jian Jian Luan, Gulsan Sucak, MD, Didier Blaise, MD, Jurgen Finke, MD, Karl-Heinz Pflüger, MD, Hendrik Veelken, MD PhD, Norbert C Gorin, MD, Xavier Poiré, MD, Arnold Ganser, Norbert Schmitz, MD, Peter Dreger, MD, Anna Sureda, MD
Journal: Blood
Blood (2012) 120 (21): 3148.
https://doi.org/10.1182/blood.V120.21.3148.3148
Published: 2012
Journal Articles

Has Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT

Curly Morris, MD, Simona Iacobelli, Gosta Gahrton, MD, Laurent Garderet, MD, Mary Drake, MBBCh, MD, Anja van Biezen, Mohamad Mohty, Didier Blaise, MD, Xavier Poiré, M.D, Marie José Kersten, Noel-Jean Milpied, MD, Stig Lenhoff, MD, PhD, Nigel H. Russell, MD, J.ürgen Finke, T. M. de Witte, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2008.
https://doi.org/10.1182/blood.V118.21.2008.2008
Published: 2011
Journal Articles

Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710.

Robert E. Gallagher, MD, Barry K. Moser, PhD, Janis Racevskis, Xavier Poiré, MD, Clara D. Bloomfield, MD, Andrew J. Carroll, PhD, Rhett Ketterling, Diane Ralston, Esther Schachter-Tokarz, Dacheng Zhou, MD, PhD, I-Ming L. Chen, DVM, MS, Richard Harvey, Greg Koval, MS, Dorie A Sher, BS, James H. Feusner, MD, Martin S. Tallman, MD, Frederick R. Appelbaum, MD, Richard A. Larson, MD, Bayard L. Powell, MD, Elisabeth Paietta, PhD, Cheryl L. Willman, MD, Wendy Stock, MD
Journal: Blood
Blood (2010) 116 (21): 1038.
https://doi.org/10.1182/blood.V116.21.1038.1038
Published: 2010
Journal Articles

Combination of a MEK Inhibitor, AZD6244, and Dual PI3K/mTOR Inhibitor, NVP-BEZ235: An Effective Therapeutic Strategy for Acute Myeloid Leukemia

Hongtao Liu, MD, PhD, Ernesto Diaz-Flores, PhD, Xavier Poiré, MD, Olatoyosi Odenike, MD, Greg Koval, MS, Greg Malnassy, MS, Pamela Ihonor, MS, Yanming Zhang, MD, Michelle M. Le Beau, PhD, Kevin Shannon, MD, Wendy Stock, MD
Journal: Blood
Blood (2010) 116 (21): 3978.
https://doi.org/10.1182/blood.V116.21.3978.3978
Published: 2010
Journal Articles

Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression.

Xavier Poiré, MD, Ernesto Diaz-Flores, PhD, Rachel Joy Bergerson, Dorie Sher, B.S., Olatoyosi Odenike, MD, Kevin Shannon, MD, David Largaespada, PhD, Wendy Stock, MD
Journal: Blood
Blood (2009) 114 (22): 1032.
https://doi.org/10.1182/blood.V114.22.1032.1032
Published: 2009
Journal Articles

Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).

Olatoyosi Odenike, Emily Curran, Neil Iyengar, Leslie Popplewell, Mark Kirschbaum, Harry P Erba, Margaret Green, Xavier Poiré, Pamela Ihonor, Ernesto Diaz-Flores, Kevin Shannon, Ehab Atallah, James L Wade, III, Maria Perdekamp, Sreenivasa Nattam, Sachdev P. Thomas, Scott E. Smith, L. Austin Doyle, Elizabeth Shima Rich, Richard A. Larson, Wendy Stock
Journal: Blood
Blood (2009) 114 (22): 2081.
https://doi.org/10.1182/blood.V114.22.2081.2081
Published: 2009